Key result
Cilostazol added to dual antiplatelet therapy significantly increased the 24-hour average heart rate to 73 bpm compared to 68 bpm with dual antiplatelet therapy at six months after drug-eluting stent implantation.
Why the study?
Does the addition of cilostazol to dual antiplatelet therapy increase heart rate and arrhythmias in patients receiving drug-eluting stents?
RCT (n=227)
Open-label with blinded evaluation
Computer-generated randomization sequence
Yes
Does the addition of cilostazol to dual antiplatelet therapy increase heart rate and arrhythmias in patients receiving drug-eluting stents?
Answers are grounded in this paper and cite their sources.
The addition of cilostazol to dual antiplatelet therapy after DES implantation significantly increases 24-hour heart rate, suggesting caution is warranted when using cilostazol in patients with baseline tachycardia.
AIMS: Cilostazol may have a positive chronotropic or pro-arrhythmic effect. However, there have been no randomized trials to confirm these effects. METHODS: This randomized prospective trial compared dual (DAT, aspirin and clopidogrel, n=114) versus triple antiplatelet therapy (TAT, DAT plus cilostazol, n=113) at baseline and after six months in patients receiving intracoronary drug-eluting stents (DES). The primary endpoint was the 24-hour heart rate (24h-HR) at six months determined using 24h-Holter ECG monitoring. The secondary endpoints were the 24h-HR ≥70 bpm, 24h-HR increase ≥5 bpm and the counts or presence of arrhythmias. RESULTS: At six months after DES implantation, the 24h-HR (73 [68-83] vs. 68 [62-75] bpm, p＜0.001), presence of a 24h-HR ≥70 bpm (71.4 vs. 47.1%, p＜0.001) and presence of a 24h-HR increase ≥5 bpm (44.8 vs. 24.5%, p=0.002) were significantly higher for the TAT group than for the DAT group. A multivariate analysis showed that the use of cilostazol (OR: 3.10, p=0.035) and a baseline 24h-HR ＜70 bpm (OR: 4.60, p＜0.001) were strong predictors of a 24h-HR increase ≥5 bpm. However, there were no significant intergroup differences in arrhythmias. CONCLUSIONS: Cilostazol appears to result in an increase in the 24h-HR after DES implantation. Therefore, some caution should be exercised regarding the use of cilostazol in patients with tachycardia, when planning DES implantation.
No takes yet. Share an insight, caveat, or question.
Kwon et al. (2014) conducted an RCT in Coronary Artery Disease (n=227). Cilostazol (Triple antiplatelet therapy) vs. Dual antiplatelet therapy (aspirin and clopidogrel) was evaluated on 24-hour average heart rate at six months (p=<0.001). Cilostazol added to dual antiplatelet therapy significantly increased the 24-hour average heart rate to 73 bpm compared to 68 bpm with dual antiplatelet therapy at six months after drug-eluting stent implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: